MARKET

SGTX

SGTX

Sigilon Therapeutics, Inc.
NASDAQ

Real-time Quotes | Nasdaq Last Sale

34.59
-0.38
-1.09%
After Hours: 34.59 0 0.00% 17:26 01/20 EST
OPEN
34.96
PREV CLOSE
34.97
HIGH
35.63
LOW
33.33
VOLUME
63.44K
TURNOVER
--
52 WEEK HIGH
54.32
52 WEEK LOW
22.00
MARKET CAP
995.86M
P/E (TTM)
-18.9763
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Sigilon Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference on January 14, 2021
Sigilon Therapeutics, Inc. (NASDAQ: SGTX), a biotechnology company that seeks to develop functional cures for chronic diseases through its Shielded Living Therapeutics(TM) platform, today announced that its President and Chief Executive Officer, Rogerio Vi...
GlobeNewswire · 01/13 12:00
BNGO, OCGN, QS and GNW among midday movers
Gainers: Check-Cap (CHEK) +185%.Bionano Genomics (BNGO) +99%.The9 (NCTY) +92%.Ocugen (OCGN) +74%.Jaguar Health (JAGX) +42%.Pandion Therapeutics (PAND) +37%.ViewRay (VRAY) +33%.Bit Digital (BTBT) +29%.AirNet Technology (ANTE) +18%.Studio City International (MSC) +18%.Losers: Calithera Biosciences (CALA) -42%.QuantumScape (QS) -39%.Beam Global
Seekingalpha · 01/04 17:45
Bionano Genomics, Ocugen leads healthcare gainers; Calithera Biosciences, Acorda Therapeutics among major losers
Gainers: Bionano Genomics (BNGO) +90%, Ocugen OCGN +72%, ViewRay VRAY +26%, Pandion Therapeutics PAND +25%, EyePoint Pharmaceuticals EYPT +21%.Losers: Calithera Biosciences CALA -41%, Acorda Therapeutics (ACOR) -16%, Sigilon Therapeutics (SGTX) -16%, Scopus BioPharma (SCPS) -13%, DermTech (DMTK) -4%.
Seekingalpha · 01/04 16:00
Benzinga's Top Upgrades, Downgrades For December 29, 2020
Upgrades * For Continental Resources Inc (NYSE:CLR), KeyBanc upgraded the previous rating of Sector Weight to Overweight. Continental Resources earned $0.16 in the third quarter, compared to $0.54 in the year-ago quarter. The current stock performance of...
Benzinga · 12/29/2020 15:12
Morgan Stanley Initiates Coverage On Sigilon Therapeutics with Equal-Weight Rating, Announces Price Target of $45
Morgan Stanley analyst Matthew Harrison initiates coverage on Sigilon Therapeutics (NASDAQ:SGTX) with a Equal-Weight rating and announces Price Target of $45.
Benzinga · 12/29/2020 13:18
The Week Ahead In Biotech (Dec. 27-Jan. 2): Data Releases, Regulatory Filings To Move Stocks
Biotech stocks advanced for a fifth straight week in thin holiday trading. The gains, however, were more modest amid worries concerning the emergence of a new strain of coronavirus in the U.K. The news flow of the week comprised mixed clinical trial readouts, COVID-19 drug and vaccine announcements, a few M&A announcements and a small-ticket IPO.
Benzinga · 12/26/2020 14:15
Seeking Alpha Catalyst Watch
Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a
Seekingalpha · 12/24/2020 18:15
The Daily Biotech Pulse: Supernus Issues Positive ADHD Readout, Sorrento Files For Emergency Use Authorization For Rapid COVID-19 Test, Inhibikase To Make Wall Street Debut
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Dec. 22)
Benzinga · 12/23/2020 13:29
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of SGTX. Analyze the recent business situations of Sigilon Therapeutics, Inc. through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 4 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average SGTX stock price target is 53.75 with a high estimate of 62.00 and a low estimate of 45.00.
EPS
Institutional Holdings
Institutions: 0
Institutional Holdings: 0
% Owned: 0.00%
Shares Outstanding: 28.79M
TypeInstitutionsShares
Increased
0
0
New
0
0
Decreased
0
0
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
No Data
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About SGTX
Sigilon Therapeutics Inc. is a clinical-stage biotechnology company seeking to develop functional cures for patients with chronic diseases by providing stable and durable levels of therapeutic molecules to patients. The Company has developed its SLTx platform, which combines advanced cell engineering with advancements in biocompatible materials and enables its product candidates to produce a wide range of therapeutic molecules that may be missing or deficient, such as proteins, antibodies and enzymes. The Company’s lead product candidate is SIG-001, which is designed to prevent bleeding episodes in patients with moderate-severe to severe Hemophilia. The Company’s other product candidates includes SIG-009, SIG-003, SIG-005, SIG-007, SIG-018, SIG-002, SIG-014 and SIG-015.
More

Webull offers kinds of Sigilon Therapeutics, Inc. stock information, including NASDAQ:SGTX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SGTX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading SGTX stock methods without spending real money on the virtual paper trading platform.